Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx reported a net loss of $41.3 million in Q1 2026, missing the consensus EPS estimate, leading to a slight stock price decline. The pivotal Phase 3 LUCIDITY clinical trial for avexitide in PBH completed enrollment in late March 2026, with top-line data anticipated in Q3 2026. Amylyx launched a U.S. Expanded Access Program for adults with post-bariatric hypoglycemia in May 2026. Several analysts have issued reports and updated price targets for AMLX. The decision to withdraw AMX0035 (Relyvrio/Albrioza) for ALS from the U.S. and Canadian markets in April 2024 had a significant and lasting impact on the stock price. Amylyx ended Q1 2026 with $279.8 million in cash and marketable securities, expected to fund operations into 2028.

There is no specific information available to indicate significant demand seasonality for Amylyx Pharmaceuticals' products or services. Demand for its products would likely be driven by disease prevalence and treatment needs rather than seasonal fluctuations.

Amylyx Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases and endocrine conditions. The company's pipeline includes Avexitide, an investigational GLP-1 receptor antagonist in Phase 3 clinical trials for post-bariatric hypoglycemia (PBH) and being studied for congenital hyperinsulinism. AMX0035, an oral fixed-dose combination therapy, is in development for Wolfram syndrome. AMX0035, previously approved for amyotrophic lateral sclerosis (ALS) but was voluntarily withdrawn from the U.S. and Canadian markets in April 2024. AMX0114, an antisense oligonucleotide targeting calpain-2, is in Phase 1 development for ALS and has received FDA Fast Track designation. AMX0318, a long-acting GLP-1 receptor antagonist, is a development candidate for PBH and other rare diseases, with IND-enabling studies underway and an IND filing targeted for 2027.

Amylyx Pharmaceuticals is based in Cambridge, Massachusetts, United States, and has expanded its global presence with subsidiaries in Canada and EMEA. The company has pursued regulatory approvals and market access for its therapies in the United States, Canada, and Europe.

Amylyx Pharmaceuticals' brand reputation has been significantly shaped by the withdrawal of its ALS drug, AMX0035, from the U.S. and Canadian markets in April 2024, following a Phase 3 trial failure. The company received praise for its ethical decision to discontinue selling the drug, which helped mitigate potential damage to its reputation. The company has since pivoted its focus and is working to rebuild confidence through its pipeline, particularly with avexitide.

Amylyx Pharmaceuticals, Inc. has a mixed ownership structure. Institutional investors hold a significant portion of the company's shares. Major institutional shareholders include Fmr Llc, BlackRock, Inc., Perceptive Advisors Llc, Vanguard Group Inc, Commodore Capital Lp, Saturn V Capital Management LLC, Janus Henderson Group Plc, First Light Asset Management, LLC, Driehaus Capital Management Llc, and Adage Capital Partners Gp, L.l.c. Approximately 39.82% of the company's stock is owned by institutional investors, 8.07% by insiders, and 52.11% by public companies and individual investors. Joseph Edelman owns the most shares of Amylyx Pharmaceuticals Inc.